Sun Nuclear competitors

Experienced public company Chief Executive Officer and board member in small and mid cap medical device/technology companies with a demonstrated history of driving shareholder value. Primary career path experience in sales management and commercial operations, strategic marketing and business development. Broad range of product/market experiences covering the full spectrum from FDA Class 3 implantable devices to multi-million dollar complex medical equipment

Mike McMullen is Agilent’s CEO-elect. He will assume the CEO position in March 2015 when William (Bill) Sullivan takes an advisory role until his retirement. As a first step in the CEO transition, McMullen has been named president and chief operating officer. McMullen has more than 30 years of industry experience and senior management experience at Agilent. He has been president of the company’s Chemical Analysis Group (CAG) since 2009, a role he still fills on an acting basis. As head of CAG, McMullen transformed the business, consistently delivering market-leading growth and profits. He championed strategic acquisitions and architected Agilent’s China strategy. He built the Agilent-wide Services business that has now been made one of Agilent’s three major businesses. McMullen has extensive experience working across Agilent’s businesses, and is recognized for his inspirational leadership style. He also has significant international experience, having lived in Japan, leading Agilent’s Japan field sales and support operations, and later adding responsibility for China field operations. McMullen joined Agilent’s predecessor, Hewlett-Packard Co., in 1984 as a financial analyst. He holds a bachelor's degree in economics and business administration from the University of Delaware and an MBA from Wharton Business School.

Joined Varian as an intern in 1999, then full time in 2001, and has held multiple cross-functional roles and executive positions during two-decade tenure with the company. Intimate understanding of healthcare, software solutions, medical devices, technology trends, reimbursement trends and strategies that lead to success in targeted channel segments globally. Marketing strategy, new product launch, portfolio strategy, M&A, P&L, restructuring, government relations, and general management experience. Consistent creation of strategies and execution against operating plans, sales goals and market objectives, including extensive experience of both high growth and slow growth periods (turnaround plans) of Varian Medical Systems journey from $500M to over $3B. Including returning Varian to double digit growth following becoming President of the $3B+ P&L of Oncology systems. Strong leadership skills with a track record of creating an inspiring vision and communicating effectively both internally/externally through developing cultural, servant leadership and focusing on people/teams to drive net promoter scores to all-time highs and enable sustainable long-term success.

Kaylie is a student University of Mississippi graduating in 2021 and is based in Oxford, Mississippi. She is a Student Worker at CIE Ole Miss and Chief Executive Officer at HEARTWARE INTERNATIONAL, INC.. Kaylie attended Southport High School between 2014 and 2018.

Lior Rauchberger is the Chief Executive Officer at Gene By Gene. Lior Rauchberger attended Monash University.

Tammi Carter is a Member at Renaissance Executive Forums and Chief Executive Officer at D4d Technologies LLC and is based in Richardson, Texas. She has worked as Director at Flex Ltd., Global Supply Chain Manager at Sanmina, and Vice President of Operations at D4d Technologies LLC. Tammi studied at Bellevue Community Center, WGU Texas between 2016 and 2018, and Flextronics University.